Derek Alan Wainwright, Ph.D., Wade F.B. Thompson CLIP InvestigatorNorthwestern University

Now, it is only a matter of time until we unlock this potential for the vast majority of malignancies.
Area of Research: Brain Cancer

Checkpoint immunotherapies targeting CTLA-4 and PD-1 have been approved for multiple cancers. However, there are many types of cancer that have yet to show promise with this treatment strategy. Dr. Wainwright is focusing on the role of IDO1 in glioblastoma, an incurable type of brain cancer. His laboratory recently demonstrated that a novel approach combining multiple immunotherapies improves survival in mice with brain tumors. Now, he’s studying the effects of this approach in humanized mice with human immune systems and human brain cancers. His group is also working with oncologists to study the clinical approach of combining immunotherapy and radiotherapy in glioblastoma patients. The insights from this work will fast-track effective new approaches into clinical trials for a cancer patient population that is currently considered “incurable.

Immunotherapy has already demonstrated promise in some cancers that were considered to be ‘incurable’. Now, it is only a matter of time until we unlock this potential for the vast majority of malignancies.

Projects and Grants

IDO1 in glioblastoma; translating work from mouse to man

Northwestern University | Brain Cancer | 2016

Let's spread the word about Immunotherapy! Click to share this page with your community.

*Immunotherapy results may vary from patient to patient.

Top